A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291Phase 3Active, not recruiting
- Lead sponsor
- Regeneron Pharmaceuticals (Industry)
- Enrollment
- 1,564 (actual)
- Start date
- 16 Jan 2023
- Primary completion
- 27 Jul 2026 (estimated)
- Study completion
- 3 Apr 2030
- Last update posted
- 6 Jul 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 3
Interventions
- Fianlimab Drug
- Cemiplimab Drug
- Pembrolizumab Drug
- Placebo Drug
Conditions and primary outcome
- Melanoma
Primary outcome
Relapse free survival (RSF) (Up to 5 Years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05608291.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05608291 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.